An Evaluation of the Effect of the Erchonia Corporation FX-405 Laser as an Adjunctive Treatment of Periodontitis
The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease.
• Subject has voluntarily signed a written informed consent form.
• Male or female 22 to 75 years of age, inclusive.
• Subject has no evidence of Localized Aggressive Periodontitis.
• Tooth loss due to periodontitis of ≤ 4 teeth.
• Two or more teeth with the following characteristics: Non 3rd molar, Periodontitis: Stage III (Severity) according to the Interdental CAL (at site of greatest loss) and RBL, as classified by the American Academy of Periodontology (AAP), No evidence of caries, No abscess infection, No previous periodontal surgery within the prior 12 months
• Subject agrees to adhere to study provided home care instructions to maintain adequate oral hygiene during the study duration.
• Subject agrees to refrain from the use of smokeless chewing tobacco for the study duration.
• Subject agrees to refrain from exceeding 40 milligrams per day of inhaled nicotine, encompassing cigarettes, electronic cigarettes, and cigars.
• Subject agrees to refrain from engaging in any other treatments for his or her periodontitis that is outside the scope of this study during his or her participation in this study